14 May 2021 - NICE has issued a final “no” to Bristol-Myers Squibb’s oral MS drug Zeposia (ozanimod), in a decision that prevents access for patients in England and Wales.

This ruling means that there will be a divide in access to Zeposia in the UK, after the Scottish Medicines Consortium allowed funding in February for the drug in patients eligible or asking for an oral treatment.

NICE’s final draft guidance from the drug cost-effectiveness body confirms a first draft decision published in January.

Read Pharmaphorum article